KOD logo

KODIAK SCIENCES INC

KODNASDAQ
🏆 #1153 by market capEarnings Nov 12US Equity
$101.73▲ $4.76 (+4.91%)
Latest quote
🔔
Track KOD
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.9%
7d▲ 18.6%
14d▲ 15.5%
30d▲ 11.6%
ytd▲ 264.0%
1y▲ 438.3%
🏦Market Cap
$6.39B
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$97.10 – $103.37
52-Week Range
$15.83 – $104.00
Volume (shares)
27,978
Avg Volume (shares)
—
Shares Outstanding
62.8M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-21.8
P/S Ratio
0.0x
EPS (TTM)
$-3.86
Dividend Yield
0.00%
Dilution (1yr)
+1.1%
KOD logo

KODIAK SCIENCES INC

KOD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$234M▲ +25.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$137M▲ +16.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$51M▼ −$47M YoY
StockOtter · stockotter.space

About KODIAK SCIENCES INC

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100
Analyst data unavailable.

Latest News & Updates

News unavailable.